Organisation paid for research Program year 2024 Source: CMS Open Payments

Florida International Research

Neither a doctor nor a teaching hospital

Research payments

$1,014,373

83 payments

Through program year 2024, Florida International Research is reported as receiving $1,014,373 in research payments, across 83 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $11,728 7
2023 Research $107,554 5
2022 Research $105,951 7
2021 Research $308,794 34
2020 Research $391,653 24
2019 Research $88,693 6

Breakdown

Who paid Research payments · program years 2019–2024
  1. AbbVie, Inc. $844,574 75 payments
  2. Eli Lilly and Company $169,799 8 payments
Studies the money was for Research payments · program years 2019–2024
  1. M16-046 $277,456 16 payments
  2. M16-045 $162,202 7 payments
  3. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $144,340 5 payments
  4. A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) $106,514 5 payments
  5. A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis $94,136 12 payments
  6. A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis $65,608 5 payments
  7. A Phase 3b, Open-Label Treatment Extension Study of Upadacitinib For the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis Who Completed Treatment in Study M16-046 $40,302 11 payments
  8. A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects with Moderate to Severe Plaque Psoriasis who have a Suboptimal Response to Secukinumab or Ixekizumab and are Switched to Risankizumab $27,964 2 payments
  9. A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis $25,495 6 payments
  10. A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease Ad Geras US $25,392 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record